CLINICAL CASE We report a case of a 42 year-old male with a macular edema due to idiopathic juxtafoveal retinal telangiectasis type i, treated with 3 sequential injections of intravitreal bevacizumab (1.25 mg in 0.05 ml). Anatomical improvements were observed after one year of follow up. DISCUSSION There is currently no general consensus regarding the treatment of unilateral idiopathic juxtaf...

PURPOSE To evaluate the efficacy of photodynamic therapy (PDT) with verteporfin and intravitreal injection of triamcinolone to treat choroidal neovascularization (CNV) with flat sub-macular hemorrhage in age-related macular degeneration (ARMD). METHODS A prospective, consecutive, noncomparative, interventional case series study was performed at the Instituto Oftalmologico de Alicante, Spain. ...

purpose: to compare intravitreal bevacizumab (ivb) with intravitreal triamcinolone acetonide (ivt) for treatment of refractory uveitic cystoid macular edema (cme). methods: in this randomized clinical trial, 31 eyes with uveitic cme were allocated into 2 groups: the ivb group, received one to three injections of 1.25 mg bevacizumab (15 eyes); the ivt group received one to three injections of 2m...

OBJECTIVE To evaluate the efficacy and safety of 1-mg and 4-mg doses of preservative-free intravitreal triamcinolone in comparison with focal/grid photocoagulation for the treatment of diabetic macular edema (DME). DESIGN Multicenter, randomized clinical trial. PARTICIPANTS Eight hundred forty study eyes of 693 subjects with DME involving the fovea and with visual acuity of 20/40 to 20/320....

purpose: to evaluate the effect of intravitreal triamcinolone acetonide injection for management of chronic refractory uveitis in terms of inflammation, visual acuity and macular thickness. methods: this interventional case series was conducted on uveitic eyes with no remission despite proper administration of periocular and/or systemic steroids. after systemic and rheumatologic evaluations and...

PURPOSE To evaluate the effect of intravitreal triamcinolone acetonide in patients with diffuse diabetic macular edema on the visual acuity and intraocular pressure. To report the potential adverse events and to analyze the potential relationship between age and visual acuity and intraocular pressure variability. METHODS This clinical controlled study included 14 patients (28 eyes), 14 of the...

AIM To report on visual outcome of patients receiving an intravitreal injection of triamcinolone acetonide for treatment of diffuse diabetic macular oedema. METHODS Prospective, comparative, non-randomised clinical interventional study included 136 patients with diffuse diabetic macular oedema. Patients of the study group (97 eyes) received an intravitreal injection of 20-25 mg of triamcinolo...

AIM To evaluate prospectively immediate intraocular pressure (IOP) changes after the intravitreal injection of ranibizumab, 2 and 4mg triamcinolone acetonide. METHODS Patients who underwent intravitreal injection of 0.1mL (4mg) triamcinolone acetonide (TA, Group T4), 0.05mL (2mg) TA (Group T2) and 0.05mL (0.5mg) ranibizumab (Group R) comprised the study population. Overall, 229 eyes of 205 pa...

PURPOSE To evaluate the midterm anatomical and functional outcomes of intravitreal injection of low-dose triamcinolone acetonide in silicone oil-filled eyes as an adjunctive treatment for proliferative vitreoretinopathy. METHODS This is a retrospective interventional case series. Patients with proliferative vitreoretinopathy grade C or D received pars plana vitrectomy combined with silicone o...